Epithalon

Epithalon (Epitalon), the synthetic pineal tetrapeptide Ala-Glu-Asp-Gly, is sold in South Africa exclusively as an unregistered research chemical for in-vitro and preclinical use. The Body Pharm Epithalon 20 pre-filled pen is the locally stocked format most often referenced by researchers in 2026. It is not SAHPRA-registered, not scheduled by name under the Medicines and Related Substances Act, and carries no approved human therapeutic indication.

For South African researchers wanting to buy Epithalon peptide locally, three practical factors matter: HPLC (High-Performance Liquid Chromatography) purity (typically ≥99% on international research-grade listings), batch-specific Certificate of Analysis (CoA) availability on request, and ZAR pricing that benchmarks against existing local listings such as Reschem's R429 Epitalon formats and Protopep's Epithalon from R660.

This guide covers what Epithalon is at the molecular level, what the research evidence actually shows about telomerase activation and circadian effects, how to source it in South Africa, and what regulatory boundaries apply.

Last updated: 2026

Key Takeaways

• Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) sold in South Africa as an unregistered research chemical with no SAHPRA approval for human use
• The evidence base is preclinical: in-vitro telomerase activation and rodent circadian-rhythm data exist, but no Phase III human trials have been published as of 2026
• The Body Pharm Epithalon 20 pen is a ready-to-use liquid format requiring 2–8 °C storage and batch-specific CoA verification before use
• South African procurement should prioritise domestic suppliers with cold-chain logistics to avoid customs delays and peptide degradation
• Regulatory status is unscheduled but unregistered; human therapeutic supply is prohibited, though laboratory research purchase is not explicitly banned

What Is Epithalon? Sequence, Origin, and Structure

Epithalon is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (AEDG), a molecular weight of 390.35 g/mol, and CAS number 307297-39-8. It is the synthetic analogue of epithalamin, a polypeptide complex originally extracted from the bovine pineal gland. In the Russian gerontology literature, researchers classify it as a short peptide bioregulator rather than a hormone.

The IUPAC designation is L-alanyl-L-glutamyl-L-aspartyl-glycine. At 390 Da, AEDG sits at the small end of the bioactive peptide range. Its low molecular weight is cited in pre-2020 literature as the basis for proposed direct interaction with promoter regions of genes including the TERT locus encoding the catalytic subunit of telomerase.

Khavinson and the St Petersburg origin

Professor Vladimir Khavinson and colleagues at the St Petersburg Institute of Bioregulation and Gerontology isolated and characterised the AEDG sequence synthetically. Their group published the foundational telomerase-activation and melatonin-modulation findings that subsequent review work has reproduced. They frame Epithalon as a peptide bioregulator: an endogenous-analogue signalling molecule that modulates gene expression at sub-hormonal concentrations. This differs from classical endocrine hormones, which operate through receptor-mediated dose-response curves.

Synthetic vs natural source

The Epithalon supplied to South African researchers in 2026, including the Body Pharm Epithalon 20 pen format, is solid-phase synthesised AEDG rather than a pineal extract. This distinction matters for purity work: synthetic AEDG is characterised by HPLC against a defined reference, whereas the historical epithalamin complex was a heterogeneous peptide mixture. Researchers benchmarking Epithalon alongside other pen-format research peptides such as Body Pharm CJC-1295 & Ipamorelin 20, or pairing it with NAD+ in cellular-ageing protocols, should request the batch CoA to confirm sequence identity and ≥98% HPLC purity before use.

Telomerase Activation: What the Research Shows

Epithalon upregulates TERT transcription and restores telomerase activity in somatic cell lines that normally lack it. The evidence base remains preclinical: as of 2026, no Phase III human randomised controlled trials on telomerase or telomere endpoints have been published. Researchers procuring AEDG should weight the mechanistic literature accordingly and avoid translating in-vitro passage data into human longevity claims.

The absence of human trials does not undermine the compound's research value. The preclinical signal is sufficiently reproducible to justify mechanistic studies in cell culture and animal models; the gap is simply that no controlled human trial has been funded or completed.

The hTERT upregulation mechanism

The proposed mechanism is direct. AEDG's small size and charge profile are cited as the basis for binding promoter regions of the TERT gene, derepressing transcription of the telomerase catalytic subunit. Reactivated telomerase then adds TTAGGG repeats to chromosome ends, extending replicative capacity in cells that had silenced TERT during differentiation. This is a transcriptional-regulator model rather than a receptor-agonist model, which is why dose-response data for Epithalon does not resemble classical pharmacology.

Key in-vitro and animal findings

The Khavinson group's foundational telomerase-activation work in human somatic cell cultures, summarised in subsequent reviews, reported increased telomerase activity and additional population doublings beyond the Hayflick limit in treated fibroblast lines. Animal models cited in the same review literature describe modulation of melatonin synthesis and circadian markers alongside lifespan effects in rodents. Vaiserman and colleagues' 2021-era review of peptide bioregulators and telomere biology continues to cite Epithalon as the prototype short-peptide telomerase modulator, while noting the absence of fresh primary human data.

What telomere elongation data actually shows

The hard numbers describe cell passages, not human lifespan. In-vitro extension of replicative capacity in fibroblast cultures, and rodent median-lifespan shifts, are the endpoints on record. None of this constitutes evidence that Epithalon extends human healthspan or reverses biological age in vivo. No peer-reviewed publication between 2023 and mid-2026 has closed that gap with a controlled human trial.

Honest framing for 2026 procurement

For a South African research lab justifying procurement, the defensible position is: Epithalon is a well-characterised tetrapeptide with reproducible in-vitro telomerase-activation signal and supportive rodent data. It is suitable for mechanistic and cellular-ageing studies in models such as senescent fibroblasts, or as a comparator alongside NAD+ precursor work. It is not a validated human therapeutic, and protocols pairing it with growth-axis peptides like the Body Pharm CJC-1295 & Ipamorelin 20 Pen should remain strictly preclinical.

Circadian Regulation and the Pineal Axis

Epithalon's second mechanistic axis is restoration of pineal melatonin output and resynchronisation of circadian markers in aged animal models. This is distinct from but biologically linked to its telomerase signal. The tetrapeptide derives from epithalamin, the original bovine pineal extract characterised by Khavinson's group, and acts on the hypothalamic-pineal axis to upregulate nocturnal melatonin synthesis where age-related decline has flattened the rhythm.

Melatonin and HPA-axis findings on record

In aged rodent and non-human primate work cited across the pineal-peptide review literature, Epithalon administration is associated with normalisation of the nocturnal melatonin peak, restoration of cortisol rhythm amplitude, and shifts in hypothalamic-pituitary-adrenal (HPA) axis reactivity toward a younger phenotype. These are the endpoints chronobiology researchers most often reference when justifying Epithalon as a probe compound. No 2023–2026 human trial has reproduced these findings under controlled conditions, so the data remains animal-model and in-vitro in character.

Where Epithalon sits among pineal peptides

Three short peptides dominate this niche: Epithalamin (the parent polypeptide extract), Epithalon (Ala-Glu-Asp-Gly, the synthetic tetrapeptide active fragment), and Pinealon (Glu-Asp-Arg, a related tripeptide). Pinealon is more often studied for neuroprotective and anti-oxidative endpoints than for telomere biology. Epithalon is the only one of the three with both a reproducible in-vitro telomerase-activation signal and a melatonin-rhythm dataset, which makes it a more versatile research tool than either of the others.

Why the dual mechanism matters for protocol design

For a chronobiology lab, this dual profile permits experimental designs that decouple replicative-senescence endpoints from circadian endpoints within a single compound. Researchers can pair fibroblast passage-limit assays with melatonin ELISA (Enzyme-Linked Immunosorbent Assay) timepoints in parallel cohorts. Researchers building broader cellular-ageing panels often run Epithalon alongside NAD+ precursor arms. Where a growth-axis comparator is needed, the Body Pharm CJC-1295 & Ipamorelin 20 Pen provides a format-matched secretagogue control for preclinical work.

Body Pharm Epithalon 20 Pen, Product Specifications

The Body Pharm Epithalon 20 Pen is a pre-filled, ready-to-use liquid pen format that ships without requiring reconstitution. It is distributed in South Africa through JCSG.org and aligned reseller channels. Body Pharm supplies the local lab market in multi-dose pen presentations, mirroring its delivery format for other compounds in the range such as the Body Pharm CJC-1295 & Ipamorelin 20 Pen.

What "20" denotes in the pen designation

The "20" suffix conventionally refers to the total peptide content of the cartridge in milligrams rather than a per-actuation dose. This pattern is inferred from analogous South African pen-format listings for GLP-1 (Glucagon-Like Peptide-1) and BPC-157 (Body Protection Compound-157) products. The exact micrograms delivered per click is not published on a public Body Pharm technical sheet as of 2026. Researchers planning dose-response work should request the product insert and a batch-specific Certificate of Analysis directly from the supplier before designing assays.

Storage, stability, and CoA scope

Liquid-format peptide pens of this class require refrigerated storage at 2–8 °C and should not be subjected to freeze-thaw cycles, which degrade tetrapeptide integrity and shift HPLC purity downward over time. South African distributors handling Body Pharm stock typically use insulated cold-chain courier services for domestic delivery, a practical consideration given inland transit times from Johannesburg to coastal labs. The Certificate of Analysis, where issued on request, covers identity confirmation, HPLC purity (research-grade Epithalon is commonly specified at ≥99% by HPLC across the international market), and residual solvent or endotoxin screening depending on batch.

Pen format versus lyophilised vial workflows

The pen removes the variability introduced by manual reconstitution with bacteriostatic water, which is the dominant source of concentration error in lyophilised vial protocols. That trade-off comes at the cost of flexibility: vial setups allow custom reconstitution volumes for specific in-vitro molarity targets, while the pen fixes the working concentration. Researchers running parallel cellular-ageing panels alongside NAD+ precursor arms tend to prefer the pen for reproducibility across long passage-limit studies.

Regulatory Status in South Africa (2026)

Epithalon is not an SAHPRA-registered medicine and is not listed by name under any schedule of the Medicines and Related Substances Act 101 of 1965 (as amended) as of 2026. The synthetic tetrapeptide Ala-Glu-Asp-Gly therefore sits outside the registered medicines framework. It cannot lawfully be advertised, supplied, or labelled for human therapeutic use in South Africa. Any vendor making clinical claims would fall under SAHPRA enforcement jurisdiction regardless of the unscheduled status.

"Unscheduled" does not mean "unregulated." The absence of a specific schedule entry does not permit human supply; it simply means the compound is not explicitly named in the controlled-substances list. SAHPRA retains authority over any material marketed as a medicine.

What "research use only" means locally

South African peptide suppliers, including those distributing Body Pharm stock, routinely apply a "not registered with SAHPRA, for research use only" disclaimer to Epithalon listings. In practical terms, that restricts legitimate use to in-vitro assays, cell-line work, and preclinical animal studies conducted under institutional oversight. It does not constitute SAHPRA authorisation, and it does not exempt the end user from compliance obligations if the material is diverted to human administration.

Institutional compliance obligations

Researchers at South African universities and private labs remain bound by their own ethics frameworks. Animal studies require Animal Research Ethics Committee (AREC) approval at the host institution. Any work touching human-derived cell lines typically routes through a Human Research Ethics Committee. Procurement records, CoA retention, and chain-of-custody documentation should be maintained per the institution's standard operating procedures. Peptides in adjacent classes such as BPC-157 and TB-500 have drawn heightened regulatory attention in other jurisdictions, worth tracking for forward planning.

Verify before purchasing

Regulatory classification can shift between gazette updates. Before placing an order, confirm the current scheduling position directly via the SAHPRA Medicines Control database and the most recent Government Gazette schedule amendments. The same caution applies to complementary longevity-pathway compounds researchers often run in parallel, including NAD+ and growth-hormone-axis tools such as the Body Pharm CJC-1295 & Ipamorelin 20 Pen.

Sourcing Epithalon in South Africa: What to Look For

Quality evaluation for research-grade Epithalon rests on four verifiable markers: HPLC purity ≥98%, sequence confirmation (Ala-Glu-Asp-Gly), batch number traceability, and cold-chain handling from dispatch to delivery. International research peptide suppliers commonly publish 98–99%+ HPLC purity with third-party lab reports for Epitalon. That range is the benchmark South African buyers should hold local suppliers to.

Local supply matters for practical reasons. Imports of unregistered peptide preparations can be flagged by SARS customs as unregistered pharmaceutical material, generating delays, seizures, or requests for SAHPRA documentation the consignee cannot produce. Lead times of two to four weeks at ambient temperature degrade lyophilised and especially liquid peptide formats. A domestic dispatch from a Johannesburg or Cape Town node, packed with ice substitute and delivered within 24–72 hours, preserves integrity in a way an unrefrigerated transcontinental parcel does not.

What JCSG.org/JCSG provides

JCSG.org stocks the Body Pharm range, including the Epithalon 20 pen, alongside complementary research compounds such as NAD+ and the Body Pharm CJC-1295 & Ipamorelin 20 Pen. Batch-specific Certificates of Analysis are not publicly linked on Body Pharm product pages. Researchers should request the CoA directly at point of order, citing the batch number printed on the cartridge or carton.

Red flags in the SA peptide market

Treat any of the following as disqualifying:

• No CoA available on request
• No batch number on the carton
• No stated HPLC purity
• Ambient-temperature shipping for liquid pens
• Vendors making therapeutic claims (a SAHPRA-relevant breach, given Epithalon is not a registered medicine)
• Vague "pharmaceutical grade" labelling without a sequence and purity figure

Epithalon vs Related Pineal Peptides, Quick Comparison

Epithalon is the most-studied synthetic pineal peptide as of 2026, with a defined tetrapeptide sequence (Ala-Glu-Asp-Gly) that distinguishes it from its natural-extract predecessor Epithalamin and from the shorter tripeptide Pinealon. All three sit within the Khavinson short-peptide bioregulator classification developed at the St Petersburg Institute of Bioregulation and Gerontology, which groups tissue-specific peptides by amino acid sequence and target organ.

Peptide	Sequence	Origin	Primary Research Use	Key Study Era
Epithalon (Epitalon)	Ala-Glu-Asp-Gly	Synthetic analogue of Epithalamin	Telomerase activation, circadian/melatonin modulation	Pre-2020 in-vitro and animal work
Epithalamin	Polypeptide mixture	Bovine pineal extract	Historical precursor; melatonin rhythm studies	1980s–1990s Russian literature
Pinealon	Ala-Glu-Asp	Synthetic tripeptide	Neuroprotective and cognitive ageing models	Pre-2020 animal studies

Epithalon's evidence volume exceeds the other two largely because its defined four-residue sequence is easier to synthesise to ≥98% HPLC purity and reproduce across laboratories. Epithalamin's extract-based composition resists standardisation. Pinealon appears in a narrower neurological literature and has not attracted comparable telomerase-focused replication.

Where NAD+ fits

For researchers building a cellular-ageing panel, NAD+ operates on a parallel but mechanistically distinct axis. It provides sirtuin substrate availability and mitochondrial redox support rather than telomere maintenance, making it a complementary rather than overlapping research compound. Laboratories running Epithalon protocols often pair it with NAD+ assays to separate telomere-length endpoints from sirtuin-driven readouts. For growth-axis comparators in the same Body Pharm pen format, the Body Pharm CJC-1295 & Ipamorelin 20 Pen is the standard cross-reference.

Storage, Handling, and Research Protocols

Store the Body Pharm Epithalon 20 pen at 2–8 °C in its original carton, protected from direct light. Keep lyophilised Epithalon powder (if sourced separately) at −20 °C for long-term stability. Ala-Glu-Asp-Gly is a short tetrapeptide whose amide and carboxyl side chains are susceptible to oxidative degradation. Avoid repeated freeze-thaw cycles. Aliquot reconstituted powder into single-use volumes rather than cycling a master vial.

For the pen format, Reschem describes South African Epitalon pens as ready-to-use liquid preparations that do not require reconstitution. The same handling logic applied to the Body Pharm CJC-1295 & Ipamorelin 20 Pen transfers directly here. Prime the device per the supplier insert before first actuation. Refrigerate between uses and discard once the printed in-use period elapses. For in-vitro work, draw from the cartridge with a 29–31 G insulin needle into sterile buffer. For preclinical rodent models, 27–29 G subcutaneous needles are standard in the published literature.

Dosing ranges in the literature

Pre-2020 rodent studies referenced in mechanistic reviews administered Epithalon at roughly 0.1–1.0 mg/kg in animal protocols. In-vitro telomerase activation was observed at nanomolar to low-micromolar concentrations in human somatic cell cultures. These are research figures, not human dosing guidance.

Record-keeping

Log batch number, CoA reference, receipt date, storage temperature excursions, reconstitution solvent and volume, and actuation count per experiment. Researchers building a cellular-ageing panel alongside NAD+ assays should record both compounds under a single study identifier to keep telomere and sirtuin endpoints traceable.

Frequently Asked Questions, Epithalon South Africa